US: KSPHF - Kissei Pharmaceutical Co. Ltd

Yield per half year: -4.6%
Dividend yield: +4.18%

Share chart Kissei Pharmaceutical Co. Ltd


About Kissei Pharmaceutical Co. Ltd

Kissei Pharmaceutical Co., Ltd. researches, develops, manufactures, and sells pharmaceutical products primarily in Japan. The company offers Kalogra tablets, for the treatment of ulcerative colitis; Tabuneos capsules for the treatment of microscopic polyangiitis and granulomatous polyangiitis; Minirin Melt OD tablets; Malizeb tablets; Tavaris tablets for the treatment of chronic idiopathic thrombocytopenic purpura; Beova tablets for the treatment of overactive bladder treatment; and Darbepoetin Alfa BS injection JCR for the treatment of renal anemia.

more details
Its products in pipeline include CG0070, which is in Phase III clinical trial to treat non-muscle-invasive bladder cancer; Linzagolix, which is in Phase III clinical trial for the treatment of uterine fibroids and endometriosis; KDT-3594, which is in Phase II clinical trial to treat Parkinson's disease; KSP-0243 that is in Phase II clinical trial to treat Ulcerative colitis; and Difelikefalin, which is in Phase III clinical trial to treat uremic pruritus in dialysis patients. The company is also developing Silodosin for dysuria associated with benign prostatic hyperplasia; and Fostamatinib for tyrosine kinase inhibitor. In addition, it develops and sells protein controlled and energy supply foods; and purchases and sells related materials, as well as offers system development and information processing, construction contracting, facility and equipment management, and information gathering and development support services. Further, the company engages in the information equipment rentals; insurance agency business; manufactures and sells noodles; and undertakes construction of factories, research institutes, offices, etc., as well as computer system design and development, and cloud services. The company was formerly known as Kissei Yakuhin Kogyo Co., Ltd. and changed its name to Kissei Pharmaceutical Co., Ltd. in October 1964. The company was incorporated in 1946 and is headquartered in Matsumoto, Japan.

Industry Pharmaceuticals
Sector Health Care
Валюта usd
Валюта отчета jpy
Див.доход ао 3.61
Дивиденд ао 0.606
Сайт https://www.kissei.co.jp
Цена ао 23.85
Change price per day: +2.67% (23.229)
Change price per week: 0% (23.85)
Change price per month: 0% (23.85)
Change price per 3 month: -0.8316% (24.05)
Change price per half year: -4.6% (25)
Change price per year: +4.24% (22.88)
Change price per 3 year: +16.34% (20.5)
Change price per 5 year: -12.64% (27.3)
Change price per year to date: -4.6% (25)

Underestimation

Title Value Grade
P/S 2.07 7
P/BV 0.709 10
P/E 14.05 8
EV/EBITDA 7.22 9
Total: 7.5

Efficiency

Title Value Grade
ROA, % 8.5 3
ROE, % 10.08 4
Total: 3.33

Dividends

Title Value Grade
Div yield, % 4.18 10
DSI 0.7857 7.86
Total: 5.6

Debt

Title Value Grade
Debt/EBITDA 0.0716 10
Total: 10

Growth impulse

Title Value Grade
Yield Revenue, % 12800.83 10
Yield Ebitda, % 45634.91 10
Yield EPS, % 711.78 10
Total: 8

Head Job title Payment Year of birth
Mr. Mutsuo Kanzawa Chairman & CEO 1949 (76 years)
Mr. Yasuo Takehana President, COO & Director 1960 (65 years)
Mr. Takahide Kitahara GM of Financial Management Department, MD & Director 1962 (63 years)
Mr. Yoshio Furihata Senior Advisor & Director 1962 (63 years)
Mr. Keiji Fukushima Executive VP & Director 1956 (69 years)
Mr. Tetsu Takayama Executive MD & Director 1961 (64 years)
Hiroshi Noake GM of Pharmaceutical Sales Headquarters & Director 1964 (61 year)
Keiji Miyazawa GM of Research Division & Director 1967 (58 years)

Address: Japan, Matsumoto, 19-48 Yoshino - open in Google maps, open in Yandex maps
Website: https://www.kissei.co.jp